These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 39363355)

  • 21. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey.
    Collin-Histed T; Rosenberg A; Hopman N; Pacey J
    Orphanet J Rare Dis; 2023 Jan; 18(1):5. PubMed ID: 36611195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosomal storage diseases.
    Platt FM; d'Azzo A; Davidson BL; Neufeld EF; Tifft CJ
    Nat Rev Dis Primers; 2018 Oct; 4(1):27. PubMed ID: 30275469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries.
    Elstein D; Giugliani R; Muenzer J; Schenk J; Schwartz IVD; Anagnostopoulou C
    Mol Genet Metab Rep; 2021 Sep; 28():100788. PubMed ID: 34367919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lysosomal storage disorders - Fabry disease and Gaucher disease].
    Segura Schmitz L; Hennermann JB; Lollert A
    Dtsch Med Wochenschr; 2024 Oct; 149(21):1263-1269. PubMed ID: 39384207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.
    Hauber B; Hong A; Hunsche E; Maculaitis MC; Collins SP
    Adv Ther; 2024 Oct; 41(10):3934-3950. PubMed ID: 39167332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry.
    Elliott S; Buroker N; Cournoyer JJ; Potier AM; Trometer JD; Elbin C; Schermer MJ; Kantola J; Boyce A; Turecek F; Gelb MH; Scott CR
    Mol Genet Metab; 2016 Aug; 118(4):304-9. PubMed ID: 27238910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Importance of lysosomal storage diseases in rheumatology].
    Aries C; Rudolph C; Muschol N
    Z Rheumatol; 2024 Jun; 83(5):393-400. PubMed ID: 38802503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan.
    Liao HC; Chiang CC; Niu DM; Wang CH; Kao SM; Tsai FJ; Huang YH; Liu HC; Huang CK; Gao HJ; Yang CF; Chan MJ; Lin WD; Chen YJ
    Clin Chim Acta; 2014 Apr; 431():80-6. PubMed ID: 24513544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.
    Mechtler TP; Stary S; Metz TF; De Jesús VR; Greber-Platzer S; Pollak A; Herkner KR; Streubel B; Kasper DC
    Lancet; 2012 Jan; 379(9813):335-41. PubMed ID: 22133539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
    Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA
    PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lysosomal storage diseases].
    Manger B
    Z Rheumatol; 2010 Aug; 69(6):527-38. PubMed ID: 20532791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.
    Hopkins PV; Campbell C; Klug T; Rogers S; Raburn-Miller J; Kiesling J
    J Pediatr; 2015 Jan; 166(1):172-7. PubMed ID: 25444528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China.
    Chen X; Qiu W; Ye J; Han L; Gu X; Zhang H
    J Hum Genet; 2016 Apr; 61(4):345-9. PubMed ID: 26740238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Creating genetics-based infusion centers: a case study of two models.
    Laney DJ; White AL; Rhead WJ; Fernhoff P
    Genet Med; 2008 Aug; 10(8):626-32. PubMed ID: 18641514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Home therapy for lysosomal storage disorders.
    Hughes DA; Mlilligan A; Mehta A
    Br J Nurs; 2007 Dec 13-2008 Jan 9; 16(22):1384, 1386-9. PubMed ID: 18361386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of complementary and alternative medicine by patients with lysosomal storage diseases.
    Balwani M; Fuerstman L; Desnick RJ; Buckley B; McGovern MM
    Genet Med; 2009 Oct; 11(10):722-7. PubMed ID: 19745751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in the understanding and treatment of Fabry disease.
    Miller JJ; Kanack AJ; Dahms NM
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129437. PubMed ID: 31526868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.